$Purple Biotech(PPBT.US)$Between now and EOY there is going to be multiple data readouts/releases! And could be some good news come out of poster presentation on June 1st? Just thinking outloud! Hehehe
$Purple Biotech(PPBT.US)$ Purple Biotech Ltd., a biotech firm trading on NASDAQ/TASE as PPBT, has a strong financial standing with a cash balance of $15.3 million and is well-positioned for upcoming clinical trial readouts in 2024. The company focuses on developing innovative first-in-class drug candidates, including CM24 for pancreatic cancer, and boasts a pipeline of potential oncology therapies. With a cash runway into the first half of 2025, Purple Biotech is advancing its leading ...
Title: Breakthrough in Pancreatic Cancer Treatment? Inside Purple Biotech's Latest Study. Pancreatic cancer remains one of the most challenging malignancies to treat, with survival rates that have seen minimal improvement over decades. However, a new beacon of hope emerges from Purple Biotech's latest clinical trial findings, which were eagerly anticipated and presented at the ASCO 2024 Annual Meeting.$Purple Biotech(PPBT.US)$ ...
Purple Biotech: A Promising Investment Frontier as Chardan Capital Maintains $11 Price Target. As we delve into the dynamic world of biotechnology, one name that stands out is Purple Biotech Ltd - ADR ($PPBT). This Israel-based clinical-stage company has been given a 'Buy' rating by Chardan Capital, a globally renowned investment bank specializing in healthcare, SPACs, and other emerging growth companies. The bank has maintained ...
$Purple Biotech(PPBT.US)$Purple Biotech Says Determined 100Mg/Kg Is The Recommended Phase 2 Dose For NT219 In Combination With Cetuximab In The Treatment Of Head And Neck Cancer Based On Its Phase 1/2 Dose Escalation Study Moomoo 24/7· just NT219 is a first-in-class small molecule dual inhibitor of IRS1/2 and STAT3. The Phase 1 dose escalation study is being concluded and the remaining patients' data are expected to be reported during the...
$Purple Biotech(PPBT.US)$Purple Biotech Says It Completed Patient Enrollment in Phase 2 Pancreatic Cancer Trial; Primary Endpoint Of The Study Is Expected During 1H 2024 And Topline Analysis Is Expected In 2H 2024 Benzinga· 1 min ago
$Purple Biotech(PPBT.US)$Q3 EPS $(0.23), Inline; $15.9M In Cash, Cash Equivalents And Short-term Deposits. In October 2023 The Company Raised An Additional Gross Amount Of $5M Extended The Cash Runway To The Second Half Of 2025 and beat EPS estimate EST -.27 ACT - .23
Sean Parker : 應該在第二季度結束前成為催化結果,這應該是任何時候。
Trytosaveabit樓主 Sean Parker: 是的,幾乎同意!GL,希望你有個愉快的週末
Sean Parker : 只是像往常一樣工作。試圖賺足夠的收益來辭職並全職做這一點。希望你一切順利。
Trytosaveabit樓主 Sean Parker: 做得很好,如果這是你真的想要並願意繼續做工作的東西嗎?從我看到的,你可以/會到達那裡!我支持你
Sean Parker Trytosaveabit樓主: 我真的很感謝你這樣說。這是我的主要重點,也是我唯一喜歡的真正愛好。你是我最喜歡的交易夥伴。你幫助我超過你所知。
查看更多評論...